BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Income Statement
Canada - TSX:BCT - CA1079303071 - Common Stock
15.9 CAD
+1.92 (+13.73%)
| TTM (2025-4-30) | 2024 (2024-7-31) | 2023 (2023-7-31) | 2022 (2022-7-31) | 2021 (2021-7-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | 201.50K | 140.10K | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 24.42M | 33.33M | 23.27M | 15.29M | 6.98M | |||
| Research and Development | 18.57M | 27.18M | 15.34M | 8.02M | 2.02M | |||
| Selling, General, and Administrative Expenses | 5.85M | 6.15M | 7.94M | 7.27M | 4.96M | |||
| Operating Income | -24.42M | -33.33M | -23.27M | -15.29M | -6.98M | |||
| Interest Income/Expense | 4.78M | 28.40M | 2.97M | -11.55M | -6.70M | |||
| Other Income/Expense | null | null | 0 | 0 | 0 | |||
| Non Recurring Items | null | null | 0 | 3.40K | -138.00K | |||
| Income Before Taxes | -19.64M | -4.93M | -20.30M | -26.84M | -13.82M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -19.43M | -4.79M | -20.30M | -26.84M | -13.82M | |||
| EBITDA | -24.27M | -33.25M | -23.26M | -15.27M | -6.96M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -82.5241 | -43.6759 | -194.9597 | -259.8174 | -458.55 | |||
| Non GAAP EPS | -83.2 | 0.8999999999999995 | -19.500000000000004 | null | null | |||
| Statistics | ||||||||
All data in USD